Arcturus Therapeutics
ARCT
136 hedge funds and large institutions have $477M invested in Arcturus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 28 closing their positions.
98% more call options, than puts
Call options by funds: $41.6M | Put options by funds: $21M
42% more capital invested
Capital invested by funds: $336M → $477M (+$140M)
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
0.21% more ownership
Funds ownership: 95.01% → 95.22% (+0.21%)
5% less funds holding
Funds holding: 143 → 136 (-7)
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.27M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.61M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$5.26M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.53M |
| 5 |
ELI
Empire Life Investments
Toronto,
Ontario, Canada
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$11.5M |
| 2 |
Goldman Sachs
New York
|
-$7.64M |
| 3 |
DAS
Diversify Advisory Services
Sandy,
Utah
|
-$3.33M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.05M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.64M |
ARCT Hedge Fund Activity: Q3 2025 in Review
136 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2025, worth a combined $477M — up 42% from $336M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ARCT and 22 opened new positions — a net loss of 6 holders — while 40 trimmed existing stakes and 49 added.
The largest buyer was Arrowstreet Capital, adding an estimated $8.27M. The largest seller was Woodline Partners, cutting an estimated $11.5M.
- 136 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2025, down from 143 in Q2 2025.
- Funds reported $477M of Arcturus Therapeutics stock for Q3 2025, up 42% quarter-over-quarter.
- 22 funds opened new Arcturus Therapeutics positions in Q3 2025 and 28 closed out, a net change of -6 holders.
- The largest Arcturus Therapeutics buyer in Q3 2025 was Arrowstreet Capital, an estimated $8.27M added.
- The largest Arcturus Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2025.